Early Phase 1 N=14 Measuring the Neuroimmune Response to Alcohol
Alcohol Drinking
Primary: Percent Change in [11C]PBR28 Distribution Volume After Alcohol Challenge. — 15.79; 6.36 [11C]PBR28 VT (% change)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Early Phase 1 N=35 taVNS Paired With Bottle Feeding in Infants Failing Oral Feeds
Poor Feeding · Infant Development · Vagus Nerve Stimulation
Primary: Number of Infants Who Took All Feeds by Mouth (Responders) — 8; 11 Participants
Early Phase 1 N=12 A Pilot Feasibility Study of Activated Charcoal in Healthy Volunteers
Healthy Adult Volunteers
Primary: Average Palatability Rating — 3.5; 4.0; 4.9; 4.4 score on a scale out of 5
Early Phase 1 N=12 Peripheral Benzodiazepine Receptors (PBR28) Brain PET Imaging With Lipopolysaccharide Challenge for the Study of Microglia Function in Alzheimer's Disease
Alzheimer Disease
Primary: Microglial Activation Reserve Index (MARI) — 17.7; 30.1 percentage of MARI — p=0.14
Early Phase 1 N=7 Transdermal Insulin Response In Healthy Volunteers
Pharmacodynamic Response to Small Doses of Insulin
Primary: Postprandial Serum Glucose in mg/dL as a Response to Small Doses (0.075 to 0.15 IUs/Kg) Human Insulin Averaged Per Subject — 3.8; -1.8; 7 mg/dL — p=0.000016
Early Phase 1 N=23 Nicotine Delivery Rate and Its Abuse Potential: Impact of Menthol
Nicotine Dependence
Primary: Peak Changes on Items of the Drug Effects Questionnaire (DEQ) - Stimulatory Effects — 7.03; 37.48; 41.91; 28.22 score on a scale
Early Phase 1 N=25 Pilot Study Using Molecular Profiling to Find Potential Targets & Select Treatments for Pts With Met br ca
Metastatic Breast Cancer
Primary: Growth Modulation Index (GMI) Greater Than or Equal to 1.3 — 25 Participants
Early Phase 1 N=62 Responses to E-Cigarette Advertising
E-Cig Use
Primary: Attention to Specific ad Feature — -1.7062; -0.9676; -1.8238 Beats per minute
Early Phase 1 N=8 Development and Translation of Generator-Produced PET Tracer for Myocardial Perfusion Imaging-Dosimetry Group
Coronary Artery Disease
Primary: Organ Dosimetry — 0.109; 0.019; 0.012; 0.034 rad/mCi
Early Phase 1 N=41 Genomic Effects of Glucocorticoids in Patients With Systemic Lupus Erythematosus
Systemic Lupus Erythematous (SLE)
Primary: Number of SLE Patients That Were Sampled for RNA-seq Differential Expression Analysis (Biological Replicates) — 20; 20; 20; 20 Participants
Early Phase 1 N=13 Naltrexone Neuroimaging
Eating Disorders · Binge Eating · Purging (Eating Disorders)
Primary: Change in % Blood Oxygenation Level Dependent Change (%BOLD) in the Nucleus Accumbens — -0.08 %BOLD signal change
Early Phase 1 N=71 Chronic Low Back Pain and Meditation
Pain
Primary: Pain Ratings — 3.60; 4.69; 4.83; 5.41 units on a scale — p=.05
Early Phase 1 N=22 Topical-RAPA Use in Inflammation Reversal and Re-setting the Epigenetic Clock
Aging · Epigenetics · Inflammatory Mediators
Primary: Change in Epigenetic Markers — 84.4; 82.8 years
Early Phase 1 N=8 Assessing the Pharmacokinetics and Drug Interaction Liability of Kratom, an Opioid-like Natural Product
Interaction Drug Food
Primary: Midazolam Area Under the Concentration vs. Time Curve (AUC) — 58.3; 80.8 nM * hr
Early Phase 1 N=3 Placental Lesions in Fetal Growth Restrictions
Fetal Growth Retardation
Primary: Number of Participants for Which Intervillous Placental Blood is Detected — 3 Participants